Asthma

New asthma inhaler propellant effective, but costlier

Published in Medical Devices and Surgical Technology Week, April 15th, 2007

A common asthma inhaler powered by a new propellant is safe and effective but could come at nearly triple the cost to consumers until a generic version hits the market, according to a review in the New England Journal of Medicine.

Conducted by two university professors and a director for the Food and Drug Administration, the review examines the consequences of switching to hydrofluoroalkane, which is replacing chlorofluorocarbon, or CFC, as a key ingredient in albuterol inhalers designed to relieve asthma. The FDA has ruled that U.S. sales of CFC albuterol inhalers be prohibited after 2008.

About 52 million prescriptions are filled for albuterol each...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week

Source: Medical Devices and Surgical Technology Week (2007-04-15)

More Articles from Medical Devices and Surgical Technology Week

Breast Cancer
MRI screening of opposite breast necessary for women with recent breast cancer diagnosis
Cancer
Protein averts cell suicide but might contribute to cancer
Cardiology
Cerebral embolic protection and carotid stent systems
Cardiology
Second generation drug-eluting stent system challenges current gold standard
Congenital Heart Disease
Studies examine issues in pediatric cardiology
Heart Transplants
Implant device effectively maintains heart function for transplant-listed patients
More from this issue of Medical Devices and Surgical Technology Week

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry